智通财经网·2026-01-22 11:52Core Viewpoint - Fosun Pharma (600196.SH) announced that its subsidiary, Jinzhou Aohong Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the drug registration application of Dextroamphetamine Injection, which is indicated for the treatment of acute hypotensive states and as an auxiliary treatment for cardiac arrest [1] Group 1 - The approved indication for the drug includes restoring blood pressure in acute hypotensive states [1] - The drug can also be used as an auxiliary treatment for cardiac arrest and to maintain blood pressure after cardiac resuscitation [1] - It serves as an auxiliary treatment for shock due to insufficient blood volume, helping to temporarily maintain cerebral and coronary perfusion until volume resuscitation takes effect [1]